查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2006214

转染技术市场：依产品、方法、应用和最终用户划分－2026-2032年全球市场预测

Transfection Technologies Market by Product, Method, Application, End-User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，转染技术市场价值将达到 13.7 亿美元，到 2026 年将成长到 14.9 亿美元，到 2032 年将达到 24.9 亿美元，复合年增长率为 8.88%。

主要市场统计数据
基准年 2025 13.7亿美元
预计年份：2026年 14.9亿美元
预测年份 2032 24.9亿美元
复合年增长率 (%) 8.88%

简述转染技术的科学基础、商业性重要性及新兴机会。

转染技术在分子生物学和治疗方法创新交叉领域发挥核心作用，为从基础基因表现研究到先进的细胞和基因疗法等一系列研究提供支持。现代实验室利用多种转染技术将核酸和其他生物分子导入细胞，从而实现基因编辑、蛋白质生产、疫苗研发和细胞株建构。鑑于平台创新步伐的加快和应用范围的不断扩大，对于学术界、工业界和临床研究领域的决策者而言，系统性地概述各种技术模式、实际权衡取舍以及相关人员的优先事项至关重要。

分析了由创新、监管趋势和不断变化的研究重点所驱动的，正在重塑转染技术格局的变革性变化。

转染领域瞬息万变，多种变革力量汇聚一堂，重塑研究流程与商业化路径。载体设计、脂质体配方和物理递送平台的创新，拓展了分子生物学家可用的工具。同时，基因组编辑和细胞疗法的同步发展，推动了对可靠且可扩展的转染解决方案的需求。此外，针对治疗应用领域良好生产规范 (GMP) 和品管的日益严格的监管要求，也迫使供应商和终端用户重新评估其产品规格和文件记录规范。

评估 2025 年美国关税措施将如何重塑供应链、采购惯例、调查工作流程和国际合作。

美国在2025年实施或修订的关税措施，将进一步增加依赖跨境分销设备、试剂及相关耗材的机构的营运复杂性。进口关税的变化可能会推高高度专业化设备和单一来源试剂的总成本，迫使采购团队重新审查与供应商的合同，协商长期协议，并探索其他替代方案，例如在地采购和区域分销合作伙伴。因此，供应链的可视性和库存策略在实验室风险管理中变得至关重要，有助于防止供应链中断造成的业务中断，并缓解成本的急剧上升。

透过整合产品、方法、应用和最终用户观点的细分洞察，我们指导所有相关人员。

细分洞察揭示了不同产品类型、调查方法、应用领域和最终用户群在需求和购买行为方面的显着差异。在产品细分中，仪器和试剂/试剂盒提供了截然不同的价值提案。仪器需要资本规划、服务模式和更长的认证週期，而试剂和试剂盒则更注重批间一致性、保质期和通讯协定检验。这种差异导致了不同的采购週期和对供应商的期望；仪器往往涉及较少但单笔金额更高的交易，而试剂则需要稳定的供应保障和品管文件。

重点区域洞察，检验美洲、欧洲、中东和非洲以及亚太地区的趋势如何影响技术采用、协作和供应链策略。

区域趋势影响着美洲、欧洲、中东和非洲（EMEA）以及亚太地区的技术采纳路径、合作模式和供应链结构。在美洲，一个研究生态系统已经形成，它汇集了世界一流的学术机构、强大的生物技术产业和活跃的临床开发项目，从而推动了对尖端仪器和检验的试剂组的强劲需求。这些使用者通常优先考虑与现有工作流程的整合以及供应商的应对力，并且倾向于选择能够提供本地支援和快速服务能力的供应商。

从企业层面深入了解生技公司和研究机构的竞争定位、伙伴关係关係、创新管道和商业化重点。

企业级趋势揭示了供应商如何透过创新管道、策略伙伴关係和商业化策略来满足客户的独特需求，从而实现差异化竞争。主要企业越来越重视端到端解决方案，将仪器、检验试剂和标准化通讯协定结合，以减轻用户的整合负担。这种方法提高了可重复性，缩短了新方法的采用时间，同时也为订阅和服务模式创造了机会，从而持续产生收入并客户维繫。

针对产业领导者的具体建议，重点在于研发投资、供应链韧性、监管参与和商业化策略。

产业领导者应采取多管齐下的策略，在增强供应链和监管韧性的同时，提昇技术差异化能力。各组织应优先进行有针对性的研发投资，以解决尚未解决的性能差距，例如提高对难以转染细胞类型的递送效率和降低细胞毒性，同时确保研发蓝图符合最终用户的检验要求。对品质系统和监管文件的同步投入将降低治疗应用临床试验的门槛，并增强对策略伙伴的吸引力。

调查方法，详细介绍资料来源、分析框架、定性专家意见以及用于确保可靠见解的检验方法。

本分析整合了以下三个面向的检验：对科学和采购领域领导者的定性访谈、对产品文献和监管指南的系统性回顾，以及体现采购和供应链应对措施的营运案例研究。该调查方法旨在平衡专家见解与文献检验，以捕捉转染技术的技术细微差别以及仪器和试剂市场的商业性现实。专家访谈提供了有关技术应用驱动因素、品质期望和营运限制的背景信息，而产品文件和检验资料集则用于比较性能特征和支援系统。

将研究、临床和商业相关人员。

本文提出的综合分析重点阐述了技术创新、营运韧性和监管准备如何共同决定转染技术在整个研究和治疗生态系统中的部署成败。其策略意义包括：产品开发需与特定应用的验证要求保持一致；加大对品质和文件的投入以支持转化应用；以及设计能够反映学术界、临床和工业界客户多样化采购行为的商业化模式。这些优先事项对于正在从概念验证(PoC) 阶段过渡到可重复且可扩展的工作流程的机构至关重要。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 转染技术市场：依产品划分

  • 装置
  • 试剂和试剂盒

第九章 转染技术市场：依方法划分

  • 生物转染
    • 质体DNA
    • 病毒载体
  • 化学转染
    • 磷酸钙转染
    • 脂质体
  • 物理转染
    • 生物转染/基因
    • 电穿孔
    • 显微注射

第十章 转染技术市场：依应用划分

  • 细胞株构建
  • CRISPR和基因编辑
  • 基因治疗
  • 蛋白质生产
  • 疫苗接种

第十一章 转染技术市场：依最终用户划分

  • 学术和研究机构
  • 合约研究组织（CRO）
  • 医院和诊断检测机构
  • 製药和生物技术公司

第十二章 转染技术市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 转染技术市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 转染技术市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国转染技术市场

第十六章：中国转染技术市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.
  • Epoch Life Science, Inc.
  • FUJIFILM Wako Pure Chemical Corporation
  • GeneCopoeia Inc.
  • Geno Technology, Inc.
  • Horizon Discovery Group plc by PerkinElmer, Inc.
  • Lonza Group
  • Maxcyte Inc.
  • Merck KGaA
  • Nepa Gene Co., Ltd.
  • OriGene Technologies, Inc.
  • OZ Biosciences SAS
  • Polyplus-transfection SA by Sartorius AG
  • Polysciences, Inc.
  • Promega Corporation
  • Qiagen NV
  • Reprocell Inc.
  • SignaGen Laboratories LLC
  • Takara Bio Inc.
  • Thermo Fisher Scientific, Inc.
Product Code: MRR-B16853779807

The Transfection Technologies Market was valued at USD 1.37 billion in 2025 and is projected to grow to USD 1.49 billion in 2026, with a CAGR of 8.88%, reaching USD 2.49 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.37 billion
Estimated Year [2026] USD 1.49 billion
Forecast Year [2032] USD 2.49 billion
CAGR (%) 8.88%

A concise introduction outlining the scientific foundations, commercial importance, and emerging opportunities within transfection technologies

Transfection technologies occupy a central role at the interface of molecular biology and therapeutic innovation, underpinning work from fundamental gene expression studies to advanced cell and gene therapies. Contemporary laboratories rely on a spectrum of transfection approaches to introduce nucleic acids and other biomolecules into cells, enabling gene editing, protein production, vaccine development, and cell line engineering. Given the accelerating pace of platform innovations and expanding application scope, an organized introduction that clarifies technology modalities, practical trade-offs, and stakeholder priorities is essential for decision-makers across academia, industry, and clinical research.

This introduction frames transfection technologies in scientific and operational contexts. It highlights the methodological diversity that influences experimental design, translation timelines, and procurement strategies. It also clarifies how reagent and instrument considerations interact with regulatory pathways and partnership models. By situating technological capabilities alongside end-user requirements, the narrative sets the stage for pragmatic prioritization, helping research directors, procurement leads, and commercialization strategists align resources to accelerate reproducible outcomes and translational impact.

Analysis of transformative shifts reshaping the transfection technology landscape driven by innovation, regulatory trends and evolving research priorities

The transfection landscape is in flux as several transformative forces converge to reshape research workflows and commercialization pathways. Innovations in vector design, lipid formulations, and physical delivery platforms have broadened the toolkit available to molecular biologists, while parallel advances in genome editing and cell therapy have elevated demand for reliable, scalable transfection solutions. At the same time, regulatory expectations around good manufacturing and quality control for therapeutic applications are tightening, prompting vendors and end users to re-evaluate product specifications and documentation practices.

Concurrently, shifting investment patterns and cross-sector partnerships are accelerating technology diffusion. Strategic collaborations between reagent developers, instrument manufacturers, and therapeutic developers are creating bundled solutions that reduce integration friction for translational programs. Moreover, growing emphasis on reproducibility and open science is encouraging standardized protocols and validated kits that reduce experimental variability. Together, these shifts point to a landscape where technological differentiation, regulatory readiness, and the ability to support end-to-end workflows determine which solutions gain sustained adoption across research, clinical, and industrial settings.

Assessment of how 2025 United States tariff actions are reshaping supply chains, procurement practices, research workflows, and international collaboration

Tariff actions enacted or modified by the United States in 2025 have introduced an additional layer of operational complexity for organizations that rely on cross-border flows of instruments, reagents, and ancillary supplies. Changes in import duties can elevate landed costs for highly specialized instruments and single-source reagents, prompting procurement teams to re-evaluate supplier agreements, negotiate longer-term contracts, and examine alternatives such as local sourcing or regional distribution partners. Consequently, supply chain mapping and inventory strategies have become more central to laboratory risk management to prevent disruptive stockouts and mitigate sudden cost escalations.

Beyond procurement, tariff shifts influence research workflows and collaboration models. Higher input costs may encourage greater consolidation of experiments to optimize reagent utilization and favor approaches that reduce per-experiment consumable use. In addition, collaborations that depend on cross-border transfer of biological materials and equipment now require more detailed contract provisions addressing customs liabilities and cost-sharing. Regulatory compliance remains a parallel concern, as changes in the origin of inputs can affect documentation and qualification processes for materials used in therapeutic development. Ultimately, while tariff adjustments do not alter the scientific imperatives driving transfection adoption, they do shape the economic and logistical decisions that determine how quickly and efficiently organizations can deploy new technologies.

Segmentation insights integrating product, method, application, and end-user perspectives to guide R&D priorities and procurement decisions across stakeholders

Segmentation insights reveal meaningful variance in needs and purchasing behavior across product categories, methodological approaches, application areas, and end-user groups. Within product segmentation, instruments and reagents & kits present distinct value propositions: instruments require capital planning, service models, and longer qualification cycles, whereas reagents and kits emphasize batch consistency, shelf life, and protocol validation. This dichotomy drives different procurement cadences and supplier expectations, with instruments often involving fewer transactions of higher value and reagents needing repeatable supply assurances and quality control documentation.

Method-based segmentation further differentiates demand. Biological transfection modalities, encompassing plasmid DNA workflows and viral vector delivery, are characterized by regulatory scrutiny and process controls suited to therapeutic applications. Chemical transfection approaches, including calcium phosphate and lipofection techniques, offer flexible bench-scale options that prioritize ease of use and reproducibility for routine experiments. Physical transfection methods such as biolistic delivery, electroporation, and microinjection address specific cell types and experimental constraints, often commanding specialized instrumentation and operator expertise. Application-driven segmentation shows that cell line development, CRISPR and gene editing, gene therapy, protein production, and vaccination each impose unique performance and validation requirements, influencing the selection of methods and suppliers. End-user segmentation indicates divergent priorities: academic and research institutes prioritize cost-effectiveness and protocol flexibility; contract research organizations emphasize throughput, reproducibility, and documented quality systems; hospitals and diagnostic laboratories require validated, regulatory-compliant inputs; and pharmaceutical and biotechnology companies prioritize scalability, regulatory alignment, and supplier risk management. Taken together, these segmentation lenses provide a framework for aligning product development, commercialization, and support services to the specific needs of each stakeholder group.

Key regional insights examining how dynamics in the Americas, EMEA, and Asia-Pacific influence technology adoption, collaborations, and supply chain strategies

Regional dynamics shape technology adoption pathways, collaboration models, and supply chain configurations across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, the research ecosystem combines world-class academic institutions, a robust biotech sector, and active clinical development programs, driving strong demand for both cutting-edge instruments and validated reagent kits. These users often prioritize integration with existing workflows and supplier responsiveness, leading to preference for vendors with local support and rapid service capabilities.

In Europe, Middle East & Africa, regulatory harmonization and cross-border collaboration influence procurement and validation practices, while national research priorities can create pockets of specialized demand. The need for documentation, QA/QC traceability, and compliance with regional regulatory frameworks encourages suppliers to provide detailed technical files and to engage in localized support. Asia-Pacific presents a heterogeneous landscape where high-volume manufacturing capacity, fast-growing research investment, and diverse regulatory regimes co-exist. Organizations in this region increasingly pursue local manufacturing partnerships and regional distribution strategies to manage costs and lead times. Across all regions, cross-border collaborations and global clinical programs necessitate coordinated supplier strategies that balance lead-time risks, customs considerations, and support infrastructures to sustain research continuity and clinical translation.

Company-level insights into competitive positioning, partnerships, innovation pipelines, and commercialization priorities across biotechnology and research firms

Company-level dynamics reveal how vendors differentiate through innovation pipelines, strategic partnerships, and commercialization approaches that address distinct customer needs. Leading firms increasingly prioritize end-to-end solutions that couple instruments with validated reagents and standardized protocols to reduce integration burden for users. This approach enhances reproducibility and shortens onboarding timelines for new methods, while also creating opportunities for subscription and service models that provide recurring revenue and customer retention.

Partnerships and alliances play a central role in accelerating market entry for novel delivery platforms and reagents. Developers of specialized reagents often collaborate with instrument manufacturers and application-focused labs to co-develop validated workflows and to demonstrate performance in real-world use cases. Moreover, companies that invest in robust regulatory documentation and quality management systems position themselves to support clinical translation and commercial manufacturing. Investment in customer support capabilities, training programs, and digital resources further differentiates providers by enabling faster adoption and greater user confidence, particularly among organizations transitioning from academic proof-of-concept work to clinical and industrial applications.

Actionable recommendations for industry leaders focusing on R&D investment, supply chain resilience, regulatory engagement, and commercialization strategies

Industry leaders should adopt a multi-dimensional strategy that strengthens technological differentiation while reinforcing supply chain and regulatory resilience. Organizations can prioritize targeted R&D investments that address unmet performance gaps-such as increasing delivery efficiency for hard-to-transfect cell types or reducing cytotoxicity-while ensuring that development roadmaps align with end-user validation requirements. Parallel investments in quality systems and regulatory documentation will reduce time-to-clinic friction for therapeutic applications and enhance attractiveness to strategic partners.

Operationally, stakeholders should diversify procurement channels and cultivate regional distribution relationships to mitigate tariff and logistics risks. This includes qualifying alternate suppliers, maintaining strategic buffer inventories for critical reagents, and negotiating service-level agreements for instrument maintenance. From a commercial perspective, companies should expand training and technical-support offerings to lower adoption barriers, develop bundled solutions that simplify workflow integration, and design pricing models that reflect the distinct procurement behaviors of academic, CRO, clinical, and industry customers. Finally, proactive regulatory engagement and participation in standards-setting initiatives will help align product design with evolving compliance expectations and support smoother translational pathways.

Research methodology overview detailing data sources, analytical frameworks, qualitative expert inputs, and validation approaches used to ensure robust insights

This analysis synthesizes evidence from primary qualitative interviews with scientific and procurement leaders, structured reviews of product literature and regulatory guidance, and triangulation against operational case studies that illustrate procurement and supply chain responses. The methodological approach balances expert input with documentary validation to capture both the technical nuances of transfection methods and the commercial realities of instrument and reagent markets. Expert interviews provided context on adoption drivers, quality expectations, and operational constraints, while product documentation and validation datasets were used to compare performance characteristics and supportability.

To ensure robustness, findings were validated through cross-checking with publicly available regulatory frameworks and institutional procurement practices, and by reviewing representative vendor claims against published application notes and peer-reviewed studies. The analytical framework emphasizes reproducibility, practical applicability, and relevance to strategic decision-making, with explicit attention to mitigating bias through the use of multiple independent information sources and transparent documentation of assumptions and inference pathways. This methodology supports actionable conclusions and targeted recommendations tailored to research, clinical, and commercial stakeholders.

Conclusive synthesis of strategic implications, priority actions, and evolving opportunities across research, clinical, and commercial stakeholders

The synthesis presented here emphasizes that technological innovation, operational resilience, and regulatory preparedness jointly determine successful adoption of transfection technologies across research and therapeutic ecosystems. Strategic implications include the need to align product development with application-specific validation requirements, to invest in quality and documentation that support translational use, and to design commercialization models that reflect the differing purchasing behaviors of academic, clinical, and industrial customers. These priorities are critical for organizations seeking to move from proof-of-concept to reproducible, scalable workflows.

Priority actions include strengthening supplier relationships and logistical planning to reduce exposure to tariff and customs volatility, investing in targeted R&D that addresses high-value performance gaps, and enhancing customer enablement through training and validated workflows. As the landscape continues to evolve, stakeholders who combine technical excellence with operational agility and proactive regulatory engagement will be best positioned to capture the long-term scientific and commercial benefits associated with advanced transfection platforms. This integrated perspective supports informed decision-making and lays out a clear set of focus areas for organizational leaders.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Transfection Technologies Market, by Product

  • 8.1. Instruments
  • 8.2. Reagents & Kits

9. Transfection Technologies Market, by Method

  • 9.1. Biological Transfection
    • 9.1.1. Plasmid DNA
    • 9.1.2. Viral Vectors
  • 9.2. Chemical Transfection
    • 9.2.1. Calcium Phosphate Transfection
    • 9.2.2. Lipofection
  • 9.3. Physical Transfection
    • 9.3.1. Biolistic Transfection/Gene Guns
    • 9.3.2. Electroporation
    • 9.3.3. Microinjection

10. Transfection Technologies Market, by Application

  • 10.1. Cell Line Development
  • 10.2. CRISPR & Gene Editing
  • 10.3. Gene Therapy
  • 10.4. Protein Production
  • 10.5. Vaccination

11. Transfection Technologies Market, by End-User

  • 11.1. Academic & Research Institutes
  • 11.2. Contract Research Organizations (CROs)
  • 11.3. Hospitals & Diagnostic Laboratories
  • 11.4. Pharmaceutical & Biotechnology Companies

12. Transfection Technologies Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Transfection Technologies Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Transfection Technologies Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Transfection Technologies Market

16. China Transfection Technologies Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Agilent Technologies, Inc.
  • 17.6. Bio-Rad Laboratories, Inc.
  • 17.7. Epoch Life Science, Inc.
  • 17.8. FUJIFILM Wako Pure Chemical Corporation
  • 17.9. GeneCopoeia Inc.
  • 17.10. Geno Technology, Inc.
  • 17.11. Horizon Discovery Group plc by PerkinElmer, Inc.
  • 17.12. Lonza Group
  • 17.13. Maxcyte Inc.
  • 17.14. Merck KGaA
  • 17.15. Nepa Gene Co., Ltd.
  • 17.16. OriGene Technologies, Inc.
  • 17.17. OZ Biosciences SAS
  • 17.18. Polyplus-transfection SA by Sartorius AG
  • 17.19. Polysciences, Inc.
  • 17.20. Promega Corporation
  • 17.21. Qiagen NV
  • 17.22. Reprocell Inc.
  • 17.23. SignaGen Laboratories LLC
  • 17.24. Takara Bio Inc.
  • 17.25. Thermo Fisher Scientific, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL TRANSFECTION TECHNOLOGIES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY METHOD, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES TRANSFECTION TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA TRANSFECTION TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY REAGENTS & KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY REAGENTS & KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY BIOLOGICAL TRANSFECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY BIOLOGICAL TRANSFECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY BIOLOGICAL TRANSFECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY BIOLOGICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PLASMID DNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PLASMID DNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PLASMID DNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY VIRAL VECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY VIRAL VECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY VIRAL VECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY CHEMICAL TRANSFECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY CHEMICAL TRANSFECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY CHEMICAL TRANSFECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY CHEMICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY CALCIUM PHOSPHATE TRANSFECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY CALCIUM PHOSPHATE TRANSFECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY CALCIUM PHOSPHATE TRANSFECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY LIPOFECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY LIPOFECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY LIPOFECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PHYSICAL TRANSFECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PHYSICAL TRANSFECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PHYSICAL TRANSFECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PHYSICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY BIOLISTIC TRANSFECTION/GENE GUNS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY BIOLISTIC TRANSFECTION/GENE GUNS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY BIOLISTIC TRANSFECTION/GENE GUNS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY ELECTROPORATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY ELECTROPORATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY ELECTROPORATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY MICROINJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY MICROINJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY MICROINJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY CELL LINE DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY CELL LINE DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY CELL LINE DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY CRISPR & GENE EDITING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY CRISPR & GENE EDITING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY CRISPR & GENE EDITING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PROTEIN PRODUCTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PROTEIN PRODUCTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PROTEIN PRODUCTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY VACCINATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY VACCINATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY VACCINATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS (CROS), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS (CROS), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS (CROS), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS TRANSFECTION TECHNOLOGIES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS TRANSFECTION TECHNOLOGIES MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS TRANSFECTION TECHNOLOGIES MARKET SIZE, BY BIOLOGICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS TRANSFECTION TECHNOLOGIES MARKET SIZE, BY CHEMICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PHYSICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS TRANSFECTION TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS TRANSFECTION TECHNOLOGIES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA TRANSFECTION TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA TRANSFECTION TECHNOLOGIES MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA TRANSFECTION TECHNOLOGIES MARKET SIZE, BY BIOLOGICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA TRANSFECTION TECHNOLOGIES MARKET SIZE, BY CHEMICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PHYSICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA TRANSFECTION TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA TRANSFECTION TECHNOLOGIES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA TRANSFECTION TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA TRANSFECTION TECHNOLOGIES MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA TRANSFECTION TECHNOLOGIES MARKET SIZE, BY BIOLOGICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA TRANSFECTION TECHNOLOGIES MARKET SIZE, BY CHEMICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PHYSICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA TRANSFECTION TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA TRANSFECTION TECHNOLOGIES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA TRANSFECTION TECHNOLOGIES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA TRANSFECTION TECHNOLOGIES MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA TRANSFECTION TECHNOLOGIES MARKET SIZE, BY BIOLOGICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA TRANSFECTION TECHNOLOGIES MARKET SIZE, BY CHEMICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PHYSICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA TRANSFECTION TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA TRANSFECTION TECHNOLOGIES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE TRANSFECTION TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE TRANSFECTION TECHNOLOGIES MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE TRANSFECTION TECHNOLOGIES MARKET SIZE, BY BIOLOGICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE TRANSFECTION TECHNOLOGIES MARKET SIZE, BY CHEMICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PHYSICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE TRANSFECTION TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE TRANSFECTION TECHNOLOGIES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST TRANSFECTION TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 115. MIDDLE EAST TRANSFECTION TECHNOLOGIES MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST TRANSFECTION TECHNOLOGIES MARKET SIZE, BY BIOLOGICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST TRANSFECTION TECHNOLOGIES MARKET SIZE, BY CHEMICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PHYSICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST TRANSFECTION TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST TRANSFECTION TECHNOLOGIES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA TRANSFECTION TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 123. AFRICA TRANSFECTION TECHNOLOGIES MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA TRANSFECTION TECHNOLOGIES MARKET SIZE, BY BIOLOGICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA TRANSFECTION TECHNOLOGIES MARKET SIZE, BY CHEMICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PHYSICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA TRANSFECTION TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA TRANSFECTION TECHNOLOGIES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC TRANSFECTION TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC TRANSFECTION TECHNOLOGIES MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC TRANSFECTION TECHNOLOGIES MARKET SIZE, BY BIOLOGICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC TRANSFECTION TECHNOLOGIES MARKET SIZE, BY CHEMICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PHYSICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC TRANSFECTION TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC TRANSFECTION TECHNOLOGIES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN TRANSFECTION TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. ASEAN TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 140. ASEAN TRANSFECTION TECHNOLOGIES MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN TRANSFECTION TECHNOLOGIES MARKET SIZE, BY BIOLOGICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN TRANSFECTION TECHNOLOGIES MARKET SIZE, BY CHEMICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PHYSICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN TRANSFECTION TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN TRANSFECTION TECHNOLOGIES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 146. GCC TRANSFECTION TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GCC TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 148. GCC TRANSFECTION TECHNOLOGIES MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 149. GCC TRANSFECTION TECHNOLOGIES MARKET SIZE, BY BIOLOGICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 150. GCC TRANSFECTION TECHNOLOGIES MARKET SIZE, BY CHEMICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 151. GCC TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PHYSICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 152. GCC TRANSFECTION TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 153. GCC TRANSFECTION TECHNOLOGIES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPEAN UNION TRANSFECTION TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPEAN UNION TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPEAN UNION TRANSFECTION TECHNOLOGIES MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPEAN UNION TRANSFECTION TECHNOLOGIES MARKET SIZE, BY BIOLOGICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPEAN UNION TRANSFECTION TECHNOLOGIES MARKET SIZE, BY CHEMICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPEAN UNION TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PHYSICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION TRANSFECTION TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION TRANSFECTION TECHNOLOGIES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 162. BRICS TRANSFECTION TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. BRICS TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 164. BRICS TRANSFECTION TECHNOLOGIES MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 165. BRICS TRANSFECTION TECHNOLOGIES MARKET SIZE, BY BIOLOGICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 166. BRICS TRANSFECTION TECHNOLOGIES MARKET SIZE, BY CHEMICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 167. BRICS TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PHYSICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS TRANSFECTION TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 169. BRICS TRANSFECTION TECHNOLOGIES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 170. G7 TRANSFECTION TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. G7 TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 172. G7 TRANSFECTION TECHNOLOGIES MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 173. G7 TRANSFECTION TECHNOLOGIES MARKET SIZE, BY BIOLOGICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 174. G7 TRANSFECTION TECHNOLOGIES MARKET SIZE, BY CHEMICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 175. G7 TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PHYSICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 176. G7 TRANSFECTION TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 177. G7 TRANSFECTION TECHNOLOGIES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 178. NATO TRANSFECTION TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. NATO TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 180. NATO TRANSFECTION TECHNOLOGIES MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 181. NATO TRANSFECTION TECHNOLOGIES MARKET SIZE, BY BIOLOGICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 182. NATO TRANSFECTION TECHNOLOGIES MARKET SIZE, BY CHEMICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 183. NATO TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PHYSICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 184. NATO TRANSFECTION TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 185. NATO TRANSFECTION TECHNOLOGIES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. UNITED STATES TRANSFECTION TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 188. UNITED STATES TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 189. UNITED STATES TRANSFECTION TECHNOLOGIES MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 190. UNITED STATES TRANSFECTION TECHNOLOGIES MARKET SIZE, BY BIOLOGICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 191. UNITED STATES TRANSFECTION TECHNOLOGIES MARKET SIZE, BY CHEMICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 192. UNITED STATES TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PHYSICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 193. UNITED STATES TRANSFECTION TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 194. UNITED STATES TRANSFECTION TECHNOLOGIES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 195. CHINA TRANSFECTION TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 196. CHINA TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 197. CHINA TRANSFECTION TECHNOLOGIES MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 198. CHINA TRANSFECTION TECHNOLOGIES MARKET SIZE, BY BIOLOGICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 199. CHINA TRANSFECTION TECHNOLOGIES MARKET SIZE, BY CHEMICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 200. CHINA TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PHYSICAL TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 201. CHINA TRANSFECTION TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 202. CHINA TRANSFECTION TECHNOLOGIES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)